カテゴリ： GlobalData, アメリカ, 企業調査

Cancer Genetics Inc (CGIX)：医療機器：M&Aディール及び事業提携情報

◆英語タイトル：Cancer Genetics Inc (CGIX) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA904C7899
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：73
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Cancer Genetics Inc (CGI) is a pharmaceutical company that provides diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic information to healthcare professionals, biopharma companies, and cancer centers. CGI provides clinical services such as expand DX, test menu, complete program, and summation report. The company offers a range of pharmacogenomics testing services for clinical oncologists, cancer centers, and research institutions, and for biotech and biopharma customers. It works in research collaboration with cancer centers to develop and validate proprietary tests. CGI is headquartered in Rutherford, New Jersey, the US.

Cancer Genetics Inc (CGIX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cancer Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Cancer Genetics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Cancer Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Cancer Genetics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Cancer Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Cancer Genetics Inc, Medical Equipment, Deal Details 11
Asset Purchase 11
Cancer Genetics Acquires Assets of Response Genetics for USD14 Million 11
Partnerships 13
PierianDx Enters into Agreement with Cancer Genetics 13
Cancer Genetics Enters into Partnership with Mendel Health 14
Cancer Genetics Enters into Agreement with Lantern Pharma 15
Cancer Genetics Partners with ApoCell for ApoStream 16
Cancer Genetics Partners with H3 Biomedicine 17
Cancer Genetics Enters into Distribution Agreement with Sayre Therapeutics 18
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 19
Cancer Genetics Italia Enters Into Distribution Agreement With Nikon Instruments 20
Merger 21
NovellusDx to Merge with Cancer Genetics 21
Equity Offering 23
Cancer Genetics Prices USD7 Million in Private Placement of Units 23
Cancer Genetics Raises USD3 Million in First Tranche of Private Placement of Shares 24
Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 25
Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 26
Cancer Genetics Raises USD12 Million in Public Offering of Shares 27
Cancer Genetics Completes Public Offering Of Shares For US$46 Million 29
Cancer Genetic Announces Public Offering Of Common Stock For Up To US$50 Million 31
Cancer Genetics Completes Underwriters’ Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For US$16 Million 32
Cancer Genetics Completes IPO For US$7 Million 33
Debt Offering 35
Cancer Genetics Raises USD2.6 Million in Private Placement of 10% Notes Due 2019 35
Acquisition 36
ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36
Cancer Genetics Inc – Key Competitors 37
Cancer Genetics Inc – Key Employees 38
Cancer Genetics Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Joint Venture 40
Recent Developments 41
Strategy And Business Planning 41
Sep 20, 2018: Cancer Genetics and NovellusDx agree to merge 41
Apr 03, 2017: Cancer Genetics and Mendel Announce Strategic Partnership Enabling Artificial Intelligence in Precision Medicine to Drive Personalized Treatment and Accelerate Clinical Trial Matching for Cancer Care 42
Financial Announcements 43
Aug 14, 2018: Cancer Genetics announces second quarter 2018 financial results 43
May 15, 2018: Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates 45
Apr 02, 2018: Cancer Genetics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Strategic Business Updates 47
Nov 09, 2017: Cancer Genetics Reports Record Third Quarter 2017 Revenue and 134% Increase in Contracted Bookings from Major Biotech and Pharmaceutical Companies 49
Aug 14, 2017: Cancer Genetics Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise 51
May 11, 2017: Cancer Genetics Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability 53
Mar 23, 2017: Cancer Genetics Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update 55
Corporate Communications 57
Jun 12, 2018: Cancer Genetics Appoints Michael McCartney As Chief Commercial Officer 57
Feb 05, 2018: Cancer Genetics Announces Resignation Of Panna Sharma As Chief Executive Officer 58
Nov 27, 2017: Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of Directors 59
Feb 22, 2017: Cancer Genetics to Receive $1.0 Million in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program 60
Legal and Regulatory 61
May 06, 2018: Kaskela Law: Shareholder Class Action Filed Against Cancer Genetics 61
Product News 62
Sep 20, 2018: Cancer Genetics offers Oncomine comprehensive assay to drive clinical trials 62
Dec 11, 2017: Cancer Genetics Advances Understanding of Immune Response and Measurement in Lymphomas by Combining PD-L1 Expression Analysis With RNA Analysis 63
Oct 30, 2017: Cancer Genetics a Leader in Personalized Medicine – Launches AntigenID, Solidifying CGI’s Position as a Precision Oncology Leader in the Fast Growing, Rapidly-Evolving Field of Immuno-Oncology Therapy & Drug Development 64
Oct 12, 2017: Cancer Genetics to Host Panel Discussion on “The Convergence of Artificial Intelligence and Healthcare – New Developments in Precision Medicine” 65
Sep 20, 2017: Cancer Genetics Announces 25th Contract Win to Provide Testing & Diagnostic Services for Combination Immuno-Oncology Clinical Trial 66
Jun 02, 2017: Cancer Genetics to Present at the 7th Annual LD Micro Invitational 67
Mar 13, 2017: Cancer Genetics to Present at “A Future Without Cancer Conference” on Friday, March 17 68
Other Significant Developments 69
Oct 08, 2018: Cancer Genetics and Cellaria partner on precision medicine tools 69
Nov 29, 2017: Cancer Genetics Initiates Partnership to Reduce Alarmingly Increasing Cancer Mortality Rates in India 70
Apr 10, 2017: Cancer Genetics is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs 71
Jan 06, 2017: Cancer Genetics Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73

List of Tables
Cancer Genetics Inc, Medical Equipment, Key Facts, 2017 2
Cancer Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Cancer Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Cancer Genetics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Cancer Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Cancer Genetics Inc, Deals By Market, 2012 to YTD 2018 9
Cancer Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Cancer Genetics Acquires Assets of Response Genetics for USD14 Million 11
PierianDx Enters into Agreement with Cancer Genetics 13
Cancer Genetics Enters into Partnership with Mendel Health 14
Cancer Genetics Enters into Agreement with Lantern Pharma 15
Cancer Genetics Partners with ApoCell for ApoStream 16
Cancer Genetics Partners with H3 Biomedicine 17
Cancer Genetics Enters into Distribution Agreement with Sayre Therapeutics 18
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 19
Cancer Genetics Italia Enters Into Distribution Agreement With Nikon Instruments 20
NovellusDx to Merge with Cancer Genetics 21
Cancer Genetics Prices USD7 Million in Private Placement of Units 23
Cancer Genetics Raises USD3 Million in First Tranche of Private Placement of Shares 24
Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 25
Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 26
Cancer Genetics Raises USD12 Million in Public Offering of Shares 27
Cancer Genetics Completes Public Offering Of Shares For US$46 Million 29
Cancer Genetic Announces Public Offering Of Common Stock For Up To US$50 Million 31
Cancer Genetics Completes Underwriters' Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For US$16 Million 32
Cancer Genetics Completes IPO For US$7 Million 33
Cancer Genetics Raises USD2.6 Million in Private Placement of 10% Notes Due 2019 35
ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36
Cancer Genetics Inc, Key Competitors 37
Cancer Genetics Inc, Key Employees 38
Cancer Genetics Inc, Other Locations 39
Cancer Genetics Inc, Subsidiaries 39
Cancer Genetics Inc, Joint Venture 40

List of Figures
Cancer Genetics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Cancer Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Cancer Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Cancer Genetics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Cancer Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Cancer Genetics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Cancer Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Cancer Genetics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Cancer Genetics Inc (CGIX)：医療機器：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Fomento de Construcciones y Contratas SA (FCC)：企業の財務・戦略的SWOT分析
    Fomento de Construcciones y Contratas SA (FCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Solartron Public Company Limited (SOLAR)：企業の財務・戦略的SWOT分析
    Solartron Public Company Limited (SOLAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Swarovski AG：企業の戦略・SWOT・財務情報
    Swarovski AG - Strategy, SWOT and Corporate Finance Report Summary Swarovski AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Purdue Pharma Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Purdue Pharma Inc (Purdue Pharma Canada), a subsidiary of Purdue Pharma LP is a research-based pharmaceutical company that offers services such as development, manufacturing and commercialization of medicines for patients and healthcare professionals. The company portfolio of products includ …
  • MNRB Holdings Berhad：企業の戦略・SWOT・財務情報
    MNRB Holdings Berhad - Strategy, SWOT and Corporate Finance Report Summary MNRB Holdings Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Lea County Electric Cooperative Inc：企業の戦略的SWOT分析
    Lea County Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Covalon Technologies Ltd (COV)-医療機器分野：企業M&A・提携分析
    Summary Covalon Technologies Ltd (Covalon) is a researcher, developer and commercialization of medical devices and healthcare technologies. The company offers advanced wound solutions, infection prevention products and perioperative care products. Covalon offers wound care products such as collagen …
  • Tailored Brands, Inc.：企業の戦略・SWOT・財務情報
    Tailored Brands, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tailored Brands, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Luye Pharma Group Co Ltd (2186)：製薬・医療：M&Aディール及び事業提携情報
    Summary Luye Pharma Group Co Ltd (Luye Pharma) is a pharmaceutical company that develops, produces and markets pharmaceutical products in the therapeutic areas of oncology, cardiovascular, metabolism and central nervous system. The company’s products include sodium aescinate for injection, xuezhikan …
  • RUAG Holding AG：企業の戦略・SWOT・財務情報
    RUAG Holding AG - Strategy, SWOT and Corporate Finance Report Summary RUAG Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Vietnam Prosperity Joint-Stock Commercial Bank (VPB)：企業の財務・戦略的SWOT分析
    Vietnam Prosperity Joint-Stock Commercial Bank (VPB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …
  • Lophius Biosciences GmbH：医療機器：M&Aディール及び事業提携情報
    Summary Lophius Biosciences GmbH (Lophius) is a biotechnology company that develops and markets T cell-based diagnostic systems and research tools in the areas of transplantation, infectious and autoimmune diseases. The company’s T-track immunoscan assay is a test in natural or induced immune modula …
  • Reckitt Benckiser Group Plc (RB.)：企業の財務・戦略的SWOT分析
    Reckitt Benckiser Group Plc (RB.) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Andersen Construction Co：企業の戦略的SWOT分析
    Andersen Construction Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Eutelsat Communications S.A. (ETL)：企業の財務・戦略的SWOT分析
    Eutelsat Communications S.A. (ETL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Nachi-Fujikoshi Corp (6474)：企業の財務・戦略的SWOT分析
    Nachi-Fujikoshi Corp (6474) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • ReShape Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary ReShape Medical Inc (ReShape Medical), a subsidiary of EnteroMedics Inc is a medical device company that offers weight loss solutions. The company provides dual intragastric balloon for weight loss. Its product comprises of ReShape Duo, a non surgical dual-intragastric balloon used in the tr …
  • Energizer Holdings, Inc.：企業の戦略・SWOT・財務情報
    Energizer Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Energizer Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Harley-Davidson, Inc.：企業の戦略・SWOT・財務情報
    Harley-Davidson, Inc. - Strategy, SWOT and Corporate Finance Report Summary Harley-Davidson, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Lam Research Corporation：企業の戦略・SWOT・財務分析
    Lam Research Corporation - Strategy, SWOT and Corporate Finance Report Summary Lam Research Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆